Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen
This study has been completed.
Study NCT00344383 Information provided by McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
First Received: June 23, 2006 Last Updated: October 19, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metrorrhagia
More general conditions related to this trial
Genital Diseases, Female
Hemorrhage
Pathologic Processes
Uterine Diseases
Uterine Hemorrhage
Additional drug interventions recognized in this trial
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Norgestimate
Polyestradiol phosphate
More general drug interventions related to this trial
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
McNeil Consumer &Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Back to top of Main Content
